MKP-5 inhibition blunts fibrotic responses in-vitro and in-vivo through negative regulation of TGFB1-induced smad3-signalling
A. Tzouvelekis (Athens, Greece), N. Xylourgidis (New Haven, United States of America), K. Min (New Haven, United States of America), T. Karampitsakos (Athens, Greece), I. Ninou (Athens, Greece), I. Barbayianni (Athens, Greece), A. Bennett (New Haven, United States of America), V. Aidinis (AthensHaven, Greece), N. Kaminski (AthensHaven, Greece)
Source: International Congress 2018 – New insights in the signalling pathways that underlie IPF pathophysiology
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Tzouvelekis (Athens, Greece), N. Xylourgidis (New Haven, United States of America), K. Min (New Haven, United States of America), T. Karampitsakos (Athens, Greece), I. Ninou (Athens, Greece), I. Barbayianni (Athens, Greece), A. Bennett (New Haven, United States of America), V. Aidinis (AthensHaven, Greece), N. Kaminski (AthensHaven, Greece). MKP-5 inhibition blunts fibrotic responses in-vitro and in-vivo through negative regulation of TGFB1-induced smad3-signalling. 5350
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: